Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person EZHIP (EZH1/2 Inhibitory Protein, also known as CXorf67), ex...
| Class:Id | Summation:9965828 |
|---|---|
| _displayName | EZHIP (EZH1/2 Inhibitory Protein, also known as CXorf67), ex... |
| _timestamp | 2025-09-15 16:07:16 |
| created | [InstanceEdit:9965840] Orlic-Milacic, Marija, 2025-09-05 |
| literatureReference | [LiteratureReference:9965829] EZHIP constrains Polycomb Repressive Complex 2 activity in germ cells [LiteratureReference:9965936] PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism [LiteratureReference:9965948] EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma [LiteratureReference:9965973] Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas |
| modified | [InstanceEdit:9965946] Orlic-Milacic, Marija, 2025-09-08 [InstanceEdit:9965954] Orlic-Milacic, Marija, 2025-09-08 [InstanceEdit:9965977] Orlic-Milacic, Marija, 2025-09-08 [InstanceEdit:9966046] Orlic-Milacic, Marija, 2025-09-09 [InstanceEdit:9966305] Orlic-Milacic, Marija, 2025-09-15 |
| text | EZHIP (EZH1/2 Inhibitory Protein, also known as CXorf67), expressed predominantly in the gonads, binds to the Polycomb Repressive Complex 2 (PRC2), limits its enzymatic activity, and lessens the interaction between the PRC2 core complex and its accessory subunits, but does not interfere with the recruitment of the PRC2 complex to chromatin (Ragazzini et al. 2019). Deletion of Ezhip in mice leads to a global increase in H3K27 dimethylation and trimethylation both during spermatogenesis and at late stages of oocyte maturation (Ragazzini et al. 2019). EZHIP is overexpressed in posterior fossa ependymoma type A (PFA), a pediatric brain tumor characterized by loss of H3K27 methylation (Pajtler et al. 2018). EZHIP co-immunoprecipitates with both EZH1- and EZH2-containing PRC2 complexes (Pajtler et al. 2018, Ragazzini et al. 2019, Jain et al. 2019, Hubner et al. 2019). An evolutionarily conserved sequence in the C-terminus of EZHIP is necessary and sufficient to inhibit PRC2 catalytic activity in vitro and in vivo by directly contacting the active site of the EZH2 subunit in a mechanism similar to the H3 K27M oncohistone (Jain et al. 2019, Hubner et al. 2019). A recombinant conserved sequence of EZHIP also inhibits the catalytic activity of recombinant EZH1-containing PRC2 complexes in vitro, similar to the H3 K27M mutant (Jain et al. 2019). CRISPR-Cas9-mediated deletion of the EZHIP gene from the human medulloblastoma cell line Daoy leads to a global increase in H3K27 methylation (Pajtler et al. 2018). |
| (summation) | [Reaction:9965835] EZHIP binds PRC2 [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by EZHIP (EZH1/2 Inhibitory Protein, also known as CXorf67), ex... (9965828)
